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Introduction and objectives. The aim was to evaluate 
the relationship between the magnitude of the variation in 
the level of glycemia during hospitalization and in-hospital 
and long-term mortality and postdischarge endpoints in 
2 groups of patients with acute coronary syndrome: those 
with and those without a previous diagnosis of diabetes.
Methods. The study included 1210 patients admitted 
for acute coronary syndrome between May 2004 and July 
2007. The study population was divided in 2 subgroups: 
patients with previous diagnosis of diabetes (n=386) 
and nondiabetics (n=824). Each subgroup was further 
divided into 4 smaller groups according to the quartile 
of glycemia variation: diabetics (Q1: <46 mg/dL; Q2: 
46-88 mg/dL; Q3: 88-164 mg/dL; Q4: ≥164 mg/dL) and 
nondiabetics (Q1: <14 mg/dL; Q2: 14-30 mg/dL; Q3: 30-
60 mg/dL; Q4: ≥60 mg/dL). Patients were followed up 
for an average of 18 months after the occurrence of the 
acute coronary syndrome.
Results. In diabetic patients, there was no relationship 
between the magnitude of the glycemia variation and 
in-hospital or postdischarge endpoints. In nondiabetics, 
no significant differences was observed in in-hospital 
mortality or morbidity; but statistically significant clinical 
differences were found during follow-up. Multivariate 
regression analysis showed that Q4 versus Q1, age ≥70 
years, and previous antiplatelet or angiotensin–converting 
enzyme inhibitor therapy were independent predictors of 
postdischarge endpoints in the nondiabetic group.
Conclusions. In nondiabetic acute coronary syndrome 
patients, the magnitude of the variation in glycemia 
observed during hospitalization was a strong independent 
predictor of postdischarge clinical endpoints. 
Key words: Admission glycemia. Magnitude of glycemia 
variation. Acute coronary syndrome. Metabolic control. 
Prognosis.
Magnitud de la variación de la glucemia:  
¿un nuevo instrumento para la evaluación  
del riesgo en el síndrome coronario agudo?
Introducción y objetivos. Evaluar la relación entre la 
magnitud de la variación de la glucemia durante la hos-
pitalización y la mortalidad hospitalaria y a largo plazo, y 
otras variables de valoración posteriores al alta, en 2 po-
blaciones con síndrome coronario agudo: pacientes con 
o sin diagnóstico previo de diabetes.
Métodos. Estudiamos a 1.210 pacientes ingresados 
por síndrome coronario agudo entre mayo de 2004 y ju-
lio de 2007. Dividimos la población en 2 subgrupos: pa-
cientes con un diagnóstico previo de diabetes (n = 386) 
y pacientes no diabéticos (n = 824). Cada una de estas 
subpoblaciones se dividió en 4 grupos, según los cuarti-
les de variación de la glucemia: diabéticos (Q1 < 46, Q2 
46-88, Q3 88-164, Q4 ≥ 164 mg/dl) y no diabéticos (Q1 
< 14, Q2 14-30, Q3 30-60, Q4 ≥ 60 mg/dl). Se efectuó 
un seguimiento durante una media de 18 meses tras el 
síndrome coronario agudo.
Resultados. En los pacientes diabéticos no hubo re-
lación alguna entre la magnitud de variación de la gluce-
mia y las variables de valoración intrahospitalarias y pos-
teriores al alta. En los no diabéticos, no se observaron 
diferencias significativas en cuanto a la morbimortalidad 
hospitalaria, pero sí hubo diferencias estadísticamente 
significativas en el seguimiento clínico. Tras un análisis 
de regresión múltiple, el cuartil Q4 frente al Q1, la edad 
≥ 70 años y los antecedentes previos de tratamiento con 
antiagregantes plaquetarios o con inhibidores de la enzi-
ma de conversión de angiotensina fueron factores pre-
dictivos independientes para las variables de valoración 
posteriores al alta en el grupo no diabético.
Conclusiones. En los pacientes con síndrome corona-
rio agudo no diabéticos, la magnitud de variación de la 
glucemia durante la hospitalización es un factor predicti-
vo independiente y potente de las variables de valoración 
posteriores al alta. 
Palabras clave: Glucemia al ingreso. Magnitud de varia-
ción de la glucemia. Síndrome coronario agudo. Control 
metabólico. Pronóstico.
See editorial on pageS 1092-4
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(n=386) and nondiabetics (n=824). Each of these 
subpopulations was divided in 4 groups, according 
to the quartiles of glycemia variation: diabetics (Q1: 
<46 mg/dL; Q2: 46-88 mg/dL; Q3: 88-164 mg/dL; 
Q4: ≥164 mg/dL) and nondiabetics (Q1: <14 mg/dL; 
Q2: 14-30 mg/dL; Q3: 30-60 mg/dL; Q4: ≥60 mg/dL). 
Patients were classified as having previous 
diabetes if they had been given that diagnosis 
in the past, if their medical records contained 
documentation of a previous history of diabetes or 
if the patient was treated with an oral antidiabetic 
agent or insulin at the time of hospital admission.
Demographic data, cardiovascular risk factors, 
comorbidities, drug treatment before and during 
hospital stay, as well as at discharge, were 
collected. Furthermore, laboratorial parameters, 
including first blood glucose upon admission, 
fasting glycemia, glycated haemoglobin (HbA1c), 
myocardium necrosis, inflammatory and renal 
function markers, haemoglobin, lipid profile, ECG 
data, and left ventricular ejection fraction evaluated 
by echocardiography were also determined. 
The use and mode of reperfusion (thrombolysis, 
percutaneous coronary intervention, and/
or coronary artery bypass grafting) was also 
documented. Moreover, in-hospital morbidity, 
including ventricular fibrillation, cardiogenic shock, 
cardiac arrest, recurrent myocardial infarction, 
and pulmonary edema were recorded and globally 
assessed.
Patients were followed during an average of 
18 months after ACS, by both revision of medical 
records and telephonic interview. Thirty-three 
patients (2.7% of total population) were lost to 
follow-up. Readmission for ACS or worsening 
heart failure, non-programmed revascularization, 
and death were considered as post-discharge 
endpoints.
Analysis of group differences was performed 
using the Kruskall-Wallis test (median [P25-P75]) 
for continuous variables and c2 test for trend for 
categorical variables. A P value less than .05 was 
considered statistically significant. Multivariate 
logistic regression analysis was then performed to 
determine independent predictors of post-discharge 
endpoints. In the multivariate logistic regression 
analysis model, clinically relevant variables were 
tested: age, smoking habits, previous treatment with 
anti platelet agents and angiotensin–converting 
enzyme inhibitor (ACE inhibitors), Killip class, 
systolic and diastolic blood pressure at admission, 
heart rate at admission, left ventricular ejection 
fraction, creatinine clearance, C-reactive protein, 
and magnitude of glycemia variation.
Kaplan-Meier analysis was used to illustrate 
follow-up mortality and post-discharge endpoints 
in non-diabetic population.
INTRODUCTION
Stress hyperglycemia is a common finding 
in patients with acute myocardial infarction 
(AMI), which has been recognized as an acute 
metabolic stress. Several studies have shown that 
hyperglycemia on admission in acute coronary 
syndrome (ACS) patients is common, being 
associated with an increased risk of death and in-
hospital morbidity.1-11
Although most studies have focused their 
attention on the prognostic value of blood glucose 
at admission, the assessment of blood glucose 
levels during hospitalization is gaining a growing 
importance. However, little is known about the 
prognostic value of the magnitude of glycemia 
variation during an ACS.
The aim of this study was to evaluate the 
impact of magnitude of glycemia variation during 
hospitalization on short and long-term prognosis, 
in 2 ACS populations—patients with and without 
previous diagnosis of diabetes—, and to identify 
independent predictors of post-discharge endpoints 
in these populations.
METHODS
We performed a retrospective analysis of a 
database including 1210 consecutive patients 
admitted to a single coronary care unit for ACS, 
between May 2004 and July 2007. 
ACS were defined according to current 
guidelines as unstable angina, non-ST elevation 
(NSTEMI), and ST elevation myocardial infarction 
(STEMI).12,13 
Casual (non-fasting) plasma glucose was 
measured at hospital admission and magnitude of 
glycemia variation was defined as the difference 
between admission glycemia and the lowest fasting 
glycemia during hospitalization.
Our population was divided in 2 subpopulations: 
patients with previous diagnosis of diabetes 
ABBREVIATIONS
ACS: acute coronary syndrome
AMI: acute myocardial infarction
NSTEMI: non-ST elevation myocardial 
infarction
STEMI: ST elevation myocardial infarction 
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in nondiabetics, while there were no differences in 
occurrence of ST elevation (11.0%, 26.5%, 26.3%, 
21.5%; P=.11) and atrial fibrillation (11.0%, 6.1%, 
12.6%, 12.9%; P=.38) in diabetic groups.
Mean glycemia level at admission was 131.6 
(48.3) mg/dL and 201 (81.6) mg/dL and fasting 
glycemia 120 (38.7) mg/dL and 177.6 (72) mg/dL, 
respectively in nondiabetics and diabetics. 
Magnitude of glycemia variation was correlated 
with higher levels of glycemia at admission and 
fasting glycemia (Tables 3 and 4).
Higher magnitude of glycemia variation was 
strongly correlated with higher necrosis and 
inflammation biomarkers in both groups, but was 
only associated with lower creatinine clearance in 
non-diabetics (Tables 3 and 4).
Regarding in-hospital drug therapy, non-
diabetics in Q4 received more glycoprotein IIb/
IIIa inhibitors, diuretics and catecholamines 
and less beta-blockers, while diabetics received 
more diuretics and less ACE inhibitors and 
beta-blockers (Tables 5 and 6). There were 
no significant differences regarding other 
pharmacological therapies, reperfusion strategies 
and coronary anatomy (except less normal 
coronaries in higher quartiles of nondiabetics) 
(Tables 5 and 6).
RESULTS
In our population, 20.5% of non-diabetic patients 
were admitted by unstable angina, 45.5% by 
NSTEMI, and 34.0% by STEMI, whereas 19.5% of 
diabetics were admitted by unstable angina, 52.1% 
by NSTEMI, and 28.4% by STEMI.
Nondiabetic patients with higher magnitude of 
glycemia variation were older, but there were no 
significant differences regarding demographics in 
the diabetic group (Tables 1 and 2). 
Risk profile was similar between quartiles. 
Furthermore, nondiabetic patients in higher 
quartiles were more often previously treated with 
diuretics and received less beta-blockers and 
nitrates, while higher quartiles of diabetics were 
more treated with insulin. There were no differences 
on other previous medications (Tables 1 and 2). 
Patients in lower quartiles of glycemia variation 
in both the nondiabetic (92.5%, 93.2%, 86.9%, 
77.8%; P<.001) and diabetic group (81.9%, 83.3%, 
71.9%, 64.6%; P<.001) had more frequent Killip 
class I on admission.
Regarding admission ECG, patients in higher 
glycemia variation groups had more frequent ST 
elevation (17.3%, 20.6%, 32.2%, 34.0%; P<.001) and 
atrial fibrillation (2.6%, 4.4%, 6.3%, 13.1%; P<.001) 
TABLE 1. Baseline Characteristics of the Nondiabetic Population
 Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL  <14 14-30 30-60 ≥60 
Patients, n 824 203 207 207 207 
Demographics      
 Male, % 70.5 69.5 67.1 77.8 67.6 .72
Mean age, y 65.9 64.1 65.0 65.3 69.1 <.001
Medical history      
 Hypertension, % 67.9 71.5 59.5 67.0 73.8 .31
 Dyslipidaemia, % 64.2 62.0 62.3 63.4 69.6 .19
 Obesity, % 45.3 44.8 45.6 44.6 46.3 .83
 Smoking habits, % 20.4 17.7 20.8 23.2 19.8 .50
 MI, % 21 21.2 16.8 20.5 25.7 .20
 CAD, % 58.2 59.7 61.8 51.7 59.7 .52
 PCI, % 13.4 17.2 11.9 11.3 13.1 .23
 CABG, % 5.4 8 3.9 4.4 5.4 .31
Prior medical therapy      
 Aspirin, % 45.9 51.6 35.8 46.7 48.9 .88
 Beta-blockers, % 31.1 37.9 34.2 32 21.5 .004
 ACE inhibitors, % 44.1 41.9 41.7 45.9 46.7 .35
 Statins, % 38.1 45.2 36.7 32.8 37.8 .19
 Nitrates, % 18.2 24.2 21.7 14.8 12.6 .006
 Diuretics, % 20.4 14.5 17.5 20.5 28.1 .005
ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
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TABLE 3. Main Laboratory Parameters of the Non-Diabetic Population
 Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL <14 14-30 30-60 ≥60
Patinets, n 824 203 207 207 207
Admission glycemia, mg/dL 116 (101.3-143.8) 100 (94-107) 110 (102-119) 126.5 (111-140) 164 (122-202)           <.001
Fasting glycemia, mg/dL 110 (97-130) 97 (90.5-102.5) 105 (97-115.3) 115.5 (102-134.3) 136 (111-178)           <.001
Peak troponin I, µg/L 11 (2-36) 2 (0-12) 8 (2-25) 18 (4-57) 20 (7-57)           <.001
C-Reactive protein, mg/dL 3 (1-9) 1 (0-4) 3 (1-6) 5 (2-11) 6 (2-13)           <.001
Creatinine clearance, mL/min 67 (47-89) 70 (49-88) 72 (51.8-95) 67 (45.8-90.3) 59 (42-81)           .008
TABLE 4. Main Laboratory Parameters of Diabetic Population
 Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL <46 46-88 88-164 ≥164
Patients, n 386 94 98 97 97
Admission glycemia, mg/dL 180 (140-239.5) 134.5 (113.8-167.3) 167 (138.8-201.3) 194.5 (156-237.8) 277 (209.5-332)     <.001
Fasting glycemia, mg/dL 161 (126-219.5) 128 (106.8-163.5) 145 (124-187.3) 178.5 (133.3-232) 226 (157-279.5)     <.001
Peak troponin I, µg/L 8 (1-26) 3 (0-15) 8 (3-31) 10 (2-26) 11 (2-55)     <.001
C-Reactive protein, mg/dL 4 (1-10) 2 (1-7) 4 (1-11) 5 (2-13) 5 (2-15)     <.001
Creatinine clearance, mL/min 58 (40-81) 64 (43-93.5) 62.5 (42.8-81) 56.5 (37.5-78.8) 54 (39-78)        .26
TABLE 2. Baseline Characteristics of the Diabetic Population
  Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL  <46 46-88 88-164 ≥164 
Patients, n 386 94 98 97 97 
Demographics      
 Male, % 66.8 70.2 69.4 62.9 64.9 .30
 Mean age, y 69.3 69.5 69.4 69.9 68.2 .64
Medical history      
 Hypertension, % 82 84.6 83.2 78.7 81.5 .44
 Dyslipidaemia, % 79.7 77.3 83.6 82.9 74.6 .71
 Obesity, % 62.4 63.3 65.6 62.4 58.1 .39
 Smoking habits, % 9.1 9.6 11.2 8.2 7.2 .44
 MI, % 30.5 27.5 31.8 30.8 31.8 .61
 CAD, % 70 70.3 70.4 66.3 73.1 .84
 PCI, % 14.5 17.8 10.5 16.8 13 .65
 CABG, % 9.3 8.7 11.3 4.3 12.6 .72
Prior medical therapy      
 Aspirin, % 47.6 47.1 50 47.8 59.4 .55
 Beta-blockers, % 29.9 32.9 29.4 26.1 31.3 .73
 ACE inhibitors, % 51.7 47.1 36.8 40.6 45.3 .79
 Statins, % 42.4 45.2 36.7 32.8 37.8 .92
 Nitrates, % 21 24.3 20.6 14.5 25 .82
 Diuretics, % 28.8 30 26.5 33.3 25 .76
 Oral antidiabetics, % 45.4 57.1 47.1 42 34.3 .007
 Insulin, % 31.4 11.4 30.9 34.8 50 <.001
ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.
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In diabetic patients there was no relationship 
between amplitude of glycemia variation and in-
hospital mortality (3.3%, 7.3%, 7.5%, 7.5%; P=.27) 
and morbidity (5.3%, 7.1%, 6.2%, 8.2%; P=.50), and 
post-discharge endpoints (38%, 50%, 40.7%, 48.6%; 
P=.39) and mortality (13.2%, 17.1%, 14.5%, 20.0%; 
P=.37). In nondiabetics, no significant differences 
were observed regarding in-hospital mortality 
(2.6%, 3.4%, 2.9%, 5.9%; P=.11) and morbidity 
(3.9%, 3.4%, 2.9%, 2.9%; P=.52); however, higher 
Left ventricular ejection fraction, evaluated by 
echocardiography, was worse in nondiabetics (58% 
[50%-60%], 55% [47.5%-60%], 52% [44%-58%], 50% 
[40%-58%]; P<.001) and diabetics (55.5% [46.3%-
60%], 50% [43%-59%], 52.0% [45%-58%], 49% [38%-
56%]; P=.016) with higher glycemia variations. 
These patients also had longer hospitalizations 
(nondiabetics, 4 [3–6], 5 [4–6], 5 [4–6], 5 [4–7] days, 
[P<.001]; and diabetics, 4 [3–5], 4 [3–6], 6 [4-7], 
6 [4–8] days, [P<.001]).
TABLE 5. In-Hospital Medical Treatment and Coronary Revascularization of Nondiabetics
 Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL  <14 4-30 30-60 ≥60 
Patients, n 824 203 207 207 207 
Aspirin, % 95.9 96.1 96.1 95.7 95.7 .78
Clopidogrel, % 71.7 73.4 70.5 72.9 70 .59
LMWH, % 97.1 95.1 98.1 97.6 97.6 .18
GP IIb/IIIa inhib, % 47.7 36.9 48.3 50.2 55.1 <.001
Nitrates, % 37.7 34 37.2 36.2 43.5 .07
Beta-blockers, % 83 87.2 85.5 84.1 75.4 .002
ACE inhibitors, % 90.7 91.1 90.3 89.4 91.8 .90
Statins, % 98.3 96.6 99 99.5 98.1 .23
Catecholamines, % 2.3 1.5 1 1.9 4.8 .02
Diuretics, % 24.6 14.3 20.3 28.5 35.3 <.001
Coronary angiography, % 62.9 60.6 64.7 63.8 62.3 .32
PCI, %a 62.9 58.6 58.3 69.6 65.2 .07
Normal coronary angiography, % 14.1 17.9 19.4 8.3 10.9 .02
ACE indicates angiotensin-converting enzyme; GP IIb/IIIa inib, glycoprotein IIb/IIIa inhibitors; LMWH, low molecular weight heparins; PCI, percutaneous coronary interventions. 
aIn the invasive strategy population.
TABLE 6. In-Hospital Medical Treatment and Coronary Revascularization of Diabetics
 Total Q1 Q2 Q3 Q4 P
Glycemia variation, mg/dL  46 46-88 88-164 ≥164 
Patients,n 386 94 98 97 97 
Aspirin, % 97.9 96.8 99 97.9 97.9 .75
Clopidogrel, % 74.1 73.4 79.6 66 77.3 .92
LMWH, % 96.9 98.9 94.9 99 94.8 .36
GP IIb/IIIa inhib, % 47.7 36.2 56.1 46.4 51.5 .12
Nitrates, % 38.9 40.4 32.7 41.2 41.2 .61
Beta-blockers, % 81.1 84 85.7 80.4 74.2 .05
ACE inhibitors, % 95.3 97.9 96.9 96.9 89.7 .01
Statins, % 98.4 98.9 99 99 96.9 .36
Catecholamines, % 4.1 2.1 3.1 4.1 7.2 .08
Diuretics, % 43.3 38.3 31.6 49.5 53.6 .005
Coronary angiography, % 50 52.1 51 50 45.9 .38
PCI, %a 63.8 59.3 64.1 72.2 60.6 .06
Normal coronary angiography, % 12.4 20.4 8 10.2 11.1 .22
ACE, angiotensin-converting enzyme; GP IIb/IIIa inib, glycoprotein IIb/IIIa inhibitors; LMWH, low molecular weight heparins; PCI, percutaneous coronary interventions. 
aIn the invasive strategy population.
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In the overall population, total number of in-
hospital morbidity events was 57, total number of 
in-hospital deaths was 52 and total number of post-
discharged endpoints was 417 (of whom 122 were 
deaths).
Multivariate logistic regression analysis showed 
that higher magnitude of glycemia variation (Q4 
amplitude of glycemia variation was associated with 
higher post-discharge endpoints (22.7%, 26.4%, 
35.7%, 44%; P<.001) and mortality (4.4%, 4.6%, 
7.9%, 15.4%; P<.001) during follow-up. Figure 1 
shows the Kaplan-Meier curves for post-discharge 
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Figure. Kaplan-Meyer curves for 
the follow-up mortality (A) and post-
discharge endpoints (B) in nondiabetic 
population.
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fasting glycemia is a more important predictor of 
30-day mortality than admission glucose alone. 
Patients with both elevated admission glucose and 
elevated fasting glucose the next day had a 3-fold 
increase in mortality.
Similarly, failure of an elevated glucose level to 
normalize within 24 h of admission is associated 
with worse prognosis.15,16 A recent published study16 
demonstrated that elevated admission and mean 
hospitalization glucose levels may be used to trigger 
a decision to institute intensive glucose control 
in hyperglycemic patients with AMI. Persistent 
hyperglycemia is a good discriminator of mortality, 
probably better than admission glucose alone in 
patients hospitalized with AMI.14-16
In our non-diabetic population, we found an 
important association between magnitude of 
glycemia variation and post-discharge endpoints 
and mortality, unlike with in-hospital prognosis. In 
contrast, magnitude of glycemia variation was not 
related to worse prognosis in diabetic patients.
Our findings are in line with previous studies,2,8-10 
which showed a different prognosis impact of 
stress hyperglycemia in patients without previously 
known diabetes and in diabetics. 
There could be several explanations for this 
evidence. First, some patients without a history of 
diabetes who develop hyperglycemia in stressful 
situations are true diabetics or have impaired 
glucose tolerance. It has been reported that 
abnormal glucose tolerance is common among 
patients with AMI who have no previous diagnosis 
of diabetes17-19 and is a strong risk factor for future 
cardiovascular events.19
However, a recent study20 showed that two-
thirds of patients with AMI who had no previous 
diagnosis of diabetes had abnormal glucose 
tolerance by OGTT one week after AMI, regardless 
of admission glucose levels, and admission 
hyperglycemia in non-diabetics did not represent 
previously undiagnosed abnormal glucose 
tolerance. 
Second, hyperglycemia in patients without 
diabetes is more often a marker of stress response 
due to more extensive myocardial damage, as a 
greater degree of stress is necessary to achieve the 
hyperglycemic state, because their metabolic control 
is usually normal. 
Elevated glycemia after ACS in diabetic patients 
may be a surrogate for poor glycaemic control, 
associated in our study with a high short and long-
term mortality, although there was not a significant 
relationship between quartiles of admission 
glycemia and higher mortality.
However, observational studies cannot distinguish 
whether glucose levels are merely risk markers 
or direct mediators of outcome following AMI. 
vs Q1) was an independent predictor of post-
discharge endpoints in non-diabetics, as were age 
and previous treatment with anti-platelet agents 
and ACE-inhibitors (Table 7). 
DISCUSSION
In this manuscript we present data on a new 
parameter to evaluate metabolic control in ACS 
patients: the magnitude of glycemia variation. Our 
results show that magnitude of glycemia variation 
was rather useful in determining post-discharge 
outcome, namely in the nondiabetic population, 
were it was an independent predictor of post-
discharge endpoints in the mean 18-month follow-
up. Logistic regression was also performed using 
post-ACS mortality (data not shown), but the 
magnitude of glycemia variation was not found to 
be an independent predictor.
According to the literature, hyperglycemia on 
hospital admission after an ACS is a common 
finding and should be considered an important 
marker of poor clinical outcome and increased 
mortality in patients with and without a history of 
diabetes.1-11
Although most studies have focused their 
attention on the prognostic value of blood 
glucose at admission, it represents only a single 
measurement in time and does not reflect the overall 
exposure to hyperglycemia during hospitalization.
There are several candidate measures to access 
the metabolic control in hospitalized patients. In 
our population, magnitude of glycemia variation 
during hospitalization was an independent 
predictor of post-discharge endpoints after ACS, in 
non-diabetic patients. 
Suleiman et al14 showed a graded relationship 
between both elevated fasting glycemia and 
admission glycemia and 30-day mortality, in 
nondiabetic patients with AMI, suggesting that 
TABLE 7. Independent Predictors of Post-Discharge 
Endpoints in Nondiabetics
 OR (95% CI) P
Q2 versus Q1 1.45 (0.70–3.01) .32
Q3 versus Q1 1.79 (0.86–3.73) .12
Q4 versus Q1 2.50 (1.22–5.12) .012
Age ≥70 years 2.41 (1.34–4.34) .003
Previous antiplatelet therapy 2.02 (1.25–3.25) .004
Previous ACE inhibitor 1.86 (1.16–2.98) .01
C-statistic =0.80. 
ACE indicates angiotensin-converting enzyme; Q, quartile.
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the entire ACS hospitalization, and not only a single 
snapshot of glucose metabolism (like admission 
glycemia) or a series of snapshots regarding the first 
24 h (like the glycemia normalization). Although 
more complex to measure, this may be a better way 
of assessing metabolic stress and metabolic control 
during ACS, namely in non-diabetic patients. 
Further studies are warranted to determine if the 
magnitude of glycemia variation adds something 
to the predictive value provided by admission 
glycemia.
All of this data, as well as the main findings of 
our study, clearly stress the importance of optimum 
metabolic control to prevent coronary events and 
their frequent poor outcome, especially in high-risk 
populations.
Study Limitations
This study was performed based on a database 
of 1210 consecutive patients admitted for ACS in 
a single centre. However, during this time period 
some patients were admitted to the emergency 
room of our hospital with the hypothesis of an ACS 
and died before being admitted in the coronary 
care unit (mainly just before or during the attempt 
of primary percutaneous coronary intervention), 
which may have somehow influenced our results. 
Only 33 patients (2.7% of the population) were lost 
to follow-up, a figure within expected results for 
a single-centre registry. The assessment of post-
discharge outcomes was made by medical records 
revision and telephonic interview; therefore, some 
events may have not been adequately censored, 
especially if they occurred out of hospital or in 
other hospitals without patient referral to our 
centre. Causes of death were based on death 
certificates, if available, but in some cases the 
source of information was a patient’s relative 
(therefore not always fully reliable). Although 
being a single-centre study, we think its results can 
be extrapolated for other ACS populations, because 
our demographic and clinical data are in line to 
those reported in most ACS registries published. 
However, large-scale clinical trials and registries are 
warranted to fully assess the predictive value of this 
and other metabolic parameters in ACS patients.
CONCLUSION
In this ACS population, magnitude of glycemia 
variation during hospitalization was an independent 
predictor of post-discharge endpoints in nondiabetic 
patients. This parameter, never before described, 
may be an important marker of metabolic control 
with prognostic value in these patients. This finding 
highlights an important potential opportunity to 
Current evidence suggests that hyperglycemia is a 
mediator of worse prognosis, directly exacerbating 
myocardial damage. Experimental and clinical 
studies have showed that hyperglycemia per se 
exacerbates myocardial necrosis in AMI.21-24 Higher 
glucose levels in AMI patients have been associated 
with higher free fatty acid concentrations, insulin 
resistance and impaired myocardial glucose use, 
thus increasing oxygen consumption and potentially 
worsening ischemia.
Acute hyperglycemia is associated with numerous 
adverse effects which lead to a poor outcome in 
ACS patients: endothelial dysfunction, platelet 
hyperreactivity, increased cytokine activation, 
increased lipolysis and free fatty acid levels, 
decreased glycolysis and glucose oxidation, 
increased oxidative stress (increased myocardial 
apoptosis), impaired microcirculatory function 
(“no-reflow” phenomenon), impaired ischemic 
preconditioning, impaired insulin secretion and 
insulin stimulated glucose uptake.24
Increased oxidative stress interferes with nitric 
oxide–mediated vasodilatation and reduces 
coronary blood flow at the microvascular level. 
In STEMI subjects, acute hyperglycemia is 
associated with decreased TIMI 3 flow before 
intervention, compared with euglycemia, and is the 
most important predictor of absence of coronary 
perfusion.25 It is interesting to note that in our 
study the performance of reperfusion therapy in 
STEMI patients did not independently influenced 
the results (data not shown).
Acute hyperglycemia is associated with 
impaired microcirculatory function (“no reflow” 
on myocardial contrast echocardiography after 
percutaneous coronary intervention), even 
in the context of angiographically successful 
recanalization.4 Preexisting HbA1c levels and 
diabetes status do not differ between subsets with 
and without “no-reflow,” suggesting that acute and 
not chronic hyperglycemia, is the dominant factor. 
There is increasing evidence that tight glycemic 
control for patients admitted into the hospital 
improves clinical outcomes, especially for patients 
with cardiovascular disease.26,27 Recently, the 
DIGAMI 2 study27 strongly supported the concept 
defended previously by van den Bergh,26 that a 
meticulous glucose control is an important goal to 
improve outcomes after ACS.
Compared to the other parameters of glucose 
metabolism control already available, namely 
admission glycemia and short-term glycemia 
normalization, the novel marker introduced in 
this study, magnitude of glycemia variation, 
has the advantage of being a more dynamic and 
“longitudinal” parameter, providing information 
about the extension of glycemia excursions during 
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